BPRDPO-56 by Molecular Targeting Technologies for Solid Tumor: Likelihood of Approval
BPRDPO-56 is under clinical development by Molecular Targeting Technologies and currently in Phase I for Solid Tumor.
Source: pharmaceutical-technology.com
Targeting Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Targeting Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Targeting Technologies Today - Breaking & Trending Today
ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative
Source: finanznachrichten.de
Molecular Targeting Technologies Inc. (MTTI): MTTI and ITM Sign Clinical Supply Agreement for n.c.a. Lutetium-177
Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical
Source: finanznachrichten.de
Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug
WEST CHESTER, Pa.--(BUSINESS WIRE)--Jan 26, 2022--
Source: heraldchronicle.com